<?xml version='1.0' encoding='utf-8'?>
<document id="30055222"><sentence text="Correlation Analysis of Potential Breast Cancer Resistance Protein Probes in Different Monolayer Systems." /><sentence text="Breast cancer resistance protein (BCRP) is a point of interest in drug-drug interaction safety testing" /><sentence text=" Therefore, a consensus probe that can be applied as victim in multiple experimental settings is of great benefit" /><sentence text=" Identification of candidates has been driven by the amount and quality of available clinical data, and as a result, drugs such as sulfasalazine and rosuvastatin have been suggested"><entity charOffset="131-144" id="DDI-PubMed.30055222.s4.e0" text="sulfasalazine" /><entity charOffset="149-161" id="DDI-PubMed.30055222.s4.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.30055222.s4.e0" e2="DDI-PubMed.30055222.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30055222.s4.e0" e2="DDI-PubMed.30055222.s4.e1" /></sentence><sentence text=" In this article, the in vitro performance of 5 possible alternatives was evaluated: atorvastatin, chlorothiazide, dantrolene, topotecan, and teriflunomide, and benchmarked against sulfasalazine and rosuvastatin in reference in vitro assays for BCRP drug-drug interaction testing"><entity charOffset="85-97" id="DDI-PubMed.30055222.s5.e0" text="atorvastatin" /><entity charOffset="99-113" id="DDI-PubMed.30055222.s5.e1" text="chlorothiazide" /><entity charOffset="115-125" id="DDI-PubMed.30055222.s5.e2" text="dantrolene" /><entity charOffset="127-136" id="DDI-PubMed.30055222.s5.e3" text="topotecan" /><entity charOffset="142-155" id="DDI-PubMed.30055222.s5.e4" text="teriflunomide" /><entity charOffset="181-194" id="DDI-PubMed.30055222.s5.e5" text="sulfasalazine" /><entity charOffset="199-211" id="DDI-PubMed.30055222.s5.e6" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e0" e2="DDI-PubMed.30055222.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e0" e2="DDI-PubMed.30055222.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e0" e2="DDI-PubMed.30055222.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e0" e2="DDI-PubMed.30055222.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e0" e2="DDI-PubMed.30055222.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e0" e2="DDI-PubMed.30055222.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e0" e2="DDI-PubMed.30055222.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e1" e2="DDI-PubMed.30055222.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e1" e2="DDI-PubMed.30055222.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e1" e2="DDI-PubMed.30055222.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e1" e2="DDI-PubMed.30055222.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e1" e2="DDI-PubMed.30055222.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e1" e2="DDI-PubMed.30055222.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e2" e2="DDI-PubMed.30055222.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e2" e2="DDI-PubMed.30055222.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e2" e2="DDI-PubMed.30055222.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e2" e2="DDI-PubMed.30055222.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e2" e2="DDI-PubMed.30055222.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e3" e2="DDI-PubMed.30055222.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e3" e2="DDI-PubMed.30055222.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e3" e2="DDI-PubMed.30055222.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e3" e2="DDI-PubMed.30055222.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e4" e2="DDI-PubMed.30055222.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e4" e2="DDI-PubMed.30055222.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e4" e2="DDI-PubMed.30055222.s5.e6" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e5" e2="DDI-PubMed.30055222.s5.e5" /><pair ddi="false" e1="DDI-PubMed.30055222.s5.e5" e2="DDI-PubMed.30055222.s5.e6" /></sentence><sentence text=" Based on the results, teriflunomide is proposed as an alternate in vitro BCRP probe"><entity charOffset="23-36" id="DDI-PubMed.30055222.s6.e0" text="teriflunomide" /></sentence><sentence text="" /></document>